Beyond Air, Inc. Urges Stockholders to Vote "FOR” All Proposals Ahead of the Upcoming Special Meeting
Beyond Air, Inc. (Nasdaq: XAIR) urged stockholders to vote “FOR” all proposals at a special meeting on June 18, 2026. The company said Nasdaq notified it on April 7, 2026 that it failed the $1.00 minimum bid price for 30 straight days, risking delisting. Proposal 1 would allow a 1-for-2 to 1-for-20 reverse split to restore compliance.
How this was made
The 30-second read
Why it matters
If Proposal 1 passes, the company intends to raise its per-share price above the Nasdaq threshold; if it fails, the stock is expected to face delisting proceedings, which can reduce liquidity and access to capital.
Market read
This is a compliance-driven corporate action with explicit delisting consequences, creating a clear catalyst window into the special meeting.
What to watch
The reverse split ratio (1-for-2 to 1-for-20) is discretionary; the eventual chosen ratio and timing could drive outsized post-vote price behavior beyond the binary approval outcome.
Background
Beyond Air is seeking shareholder approval for a reverse stock split after Nasdaq notified it is below the $1.00 minimum bid price requirement for continued listing.
Ticker impact
Beyond Air discloses Nasdaq notified it no longer meets the $1.00 minimum bid price requirement and seeks a reverse split to avoid delisting.
Elevated volatility into the June 18 vote; if Proposal 1 fails, delisting risk likely pressures the stock further.
The article centers on a Nasdaq compliance-driven reverse split proposal (1-for-2 to 1-for-20) with explicit delisting consequences if not approved.
Market effects
Highlights ongoing Nasdaq listing-compliance pressure risk for small-cap clinical-stage biopharma names trading below $1.
Primarily impacts US microcap liquidity and institutional eligibility rather than broader regional fundamentals.
Limited direct global spillover; delisting mechanics are US-market specific.
Counterpoint
Even with delisting risk, some investors may treat reverse-split outcomes as a liquidity/technical event rather than a fundamental impairment, trading the probability of approval.
Key entities
- companyBeyond Air, Inc.
Clinical-stage biopharma/medical device company seeking a reverse stock split to maintain Nasdaq listing.
- regulatorNasdaq Listing Qualifications Department
Notified the company it no longer satisfies the $1.00 minimum bid price requirement.
- executiveRobert Goodman
CEO urging stockholders to vote FOR all proposals.
